Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Clinical trial NCT03938987 · RECRUITING

Trial details

NCT number: NCT03938987
Sponsor: University of Alberta
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed Non Hodgkin Lymphoma Relapsed Adult ALL Relapsed Pediatric ALL

Start date: 2021-03-03
Primary completion: 2026-12-01
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.